Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
SAN DIEGO, Feb. 02, 2016 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 9:30 a.m. Eastern Time. The conference will be held at The Waldorf Astoria, New York, NY. Mr. Pascoe will provide an update on Vitaros®, the Company's topical treatment for erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.
A live audio webcast of the presentation can be accessed via the Investor Relations section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud's phenomenon, and plans to conduct additional clinical trials in patients with Raynaud's phenomenon secondary to scleroderma. Apricus' lead commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus recently in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus' marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus' second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Institutional / Retail Investors: Matthew Beck [email protected] The Trout Group LLC (646) 378-2933
